BioSpace News Archive

Pharm Country

HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced the pricing of an underwritten public offering of 21,700,000 shares of its common stock and 15,800 shares of its non-voting Series A-1 convertible preferred stock.

March 2, 2022
·
4 min read
Genetown

Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at Raymond James Institutional Investors Conference.

March 2, 2022
·
3 min read
Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing

Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured £30.75 million ($41.20 million) in an oversubscribed Series B financing round.

March 2, 2022
·
6 min read
Deals

IMA Group Continues National Growth with Acquisition of Amici Clinical Research

The IMA Group (IMA) announced today the acquisition of Amici Clinical Research, a clinical trials company with two New Jersey sites in Raritan and Hoboken.

March 2, 2022
·
3 min read
BioCapital

As Mental Health Disorders Skyrocket Among Teens and Young Adults, GENETWORx Offers Pharmacogenetic Approach that Improves Ability to Treat Patients with the Right Medication at the Right Dose

Bill Introduced in the U.S. House Seeks Reduction of Adverse Drug Reactions by Raising Awareness and Utilization of Pharmacogenetic Testing.

March 2, 2022
·
4 min read
Business

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021

Surface Oncology today reported financial results and corporate highlights for the fourth quarter and full year 2021, as well as anticipated 2022 corporate milestones.

March 2, 2022
·
11 min read
Business

Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics

Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company, today announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina.

March 2, 2022
·
6 min read
Drug Development

Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to EnrollmentCohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM.

March 2, 2022
·
7 min read
Deals

Aceto Acquires Biotron Laboratories and Talus Mineral Company (Collectively “Biotron”), Leading Manufacturers of Specialty Ingredients for the Nutritional Supplements Industry

Acquisition Brings 40 Years of Leadership In Applying Proprietary Processes and Expertise to the Development and Manufacture of Mineral Chelates and Other Specialty Ingredients for Nutritional Supplements.

March 2, 2022
·
5 min read
Lone Star Bio

Apollo Endosurgery to Participate in the Cowen Healthcare Conference

Apollo Endosurgery, Inc. today announced that Chas McKhann, CEO, and Jeff Black, CFO, will host investor meetings March 7-8, 2022 as part of the Cowen Healthcare Conference, taking place virtually.

March 2, 2022
·
1 min read